These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 34299462

  • 1. Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents.
    Han C, Shen K, Wang S, Wang Z, Su F, Wu X, Hu X, Li M, Han J, Wu L.
    Molecules; 2021 Jul 09; 26(14):. PubMed ID: 34299462
    [Abstract] [Full Text] [Related]

  • 2. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R, Zhao X, Yu S, Chen Y, Cui H, Wu T, Hao C, Zhao D, Cheng M.
    Bioorg Chem; 2020 Sep 09; 102():104092. PubMed ID: 32707280
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R, Chen Y, Zhao X, Yu S, Yang B, Wu T, Guo J, Hao C, Zhao D, Cheng M.
    Eur J Med Chem; 2019 Dec 01; 183():111716. PubMed ID: 31550660
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
    Dao P, Lietha D, Etheve-Quelquejeu M, Garbay C, Chen H.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1727-1730. PubMed ID: 28284808
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
    Li R, Gong L, Sun J, Liang Z, He J, Huang J, Ning X, Song H, Li R, Zhang Q, Lin Z, Yin Y.
    Bioorg Chem; 2024 Mar 15; 144():107134. PubMed ID: 38237389
    [Abstract] [Full Text] [Related]

  • 8. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
    Kassab AE, Hassan RA.
    Bioorg Chem; 2018 Oct 15; 80():531-544. PubMed ID: 30014921
    [Abstract] [Full Text] [Related]

  • 9. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M, Abd El-Hafeez AA, Abdelhamid D, Katkar GD, Mostafa YA, Ghosh P, Hayallah AM, Abuo-Rahma GEA.
    Eur J Med Chem; 2021 Oct 15; 222():113569. PubMed ID: 34111829
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T, Liu Y, Shi M, Tang M, Si W, Yuan X, Wen Y, Chen L.
    Bioorg Med Chem Lett; 2021 Dec 15; 54():128433. PubMed ID: 34757216
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
    Zhang S, Luo Y, He LQ, Liu ZJ, Jiang AQ, Yang YH, Zhu HL.
    Bioorg Med Chem; 2013 Jul 01; 21(13):3723-9. PubMed ID: 23673215
    [Abstract] [Full Text] [Related]

  • 13. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y, Li R, Ning X, Lin Z, Zhao X, Zhou J, Liu J, Jin Y, Yin Y.
    Eur J Med Chem; 2019 Sep 01; 177():32-46. PubMed ID: 31129452
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H, Lin X, Zhang Y, Tan F, Chi B, Peng Z, Dong W, An D.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127459. PubMed ID: 32784087
    [Abstract] [Full Text] [Related]

  • 15. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Nov 01; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P, Smith N, Tomkiewicz-Raulet C, Yen-Pon E, Camacho-Artacho M, Lietha D, Herbeuval JP, Coumoul X, Garbay C, Chen H.
    J Med Chem; 2015 Jan 08; 58(1):237-51. PubMed ID: 25180654
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S, Zhang RH, Zhang H, Wang YC, Yang D, Zhao YL, Yan GY, Xu GB, Guan HY, Zhou YH, Cui DB, Liu T, Li YJ, Liao SG, Zhou M.
    Eur J Med Chem; 2021 Oct 15; 222():113573. PubMed ID: 34091209
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226.
    Chen T, Liu Y, Liu J, Tang M, Huang H, Bai C, Si W, Yang T, Yuan X, Wen Y, Chen L.
    Bioorg Chem; 2022 Jul 15; 124():105790. PubMed ID: 35452915
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
    Qu M, Liu Z, Zhao D, Wang C, Zhang J, Tang Z, Liu K, Shu X, Yuan H, Ma X.
    Bioorg Med Chem; 2017 Aug 01; 25(15):3989-3996. PubMed ID: 28576633
    [Abstract] [Full Text] [Related]

  • 20. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N, Naomoto Y.
    Clin Cancer Res; 2008 Jul 15; 14(14):4631-9. PubMed ID: 18628478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.